-
-
-
-
-
-
-
Key Takeaways from Virtual Generics & Biosimilars Day at UBS
-
-
-
-
-
-
-
Amneal Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
-
-
-
-
-
-
-
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
-
-
-
-
-
-
-
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
-
-
-
-
-
-
-
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
-
-
-
-
-
-
-
Amneal Pharmaceuticals (AMRX) Receives First Product Approval in China
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

